A One Health approach to antimicrobial resistance surveillance: is there a business case for it?

Queenan, Kevin; Häsler, Barbara; Rushton, Jonathan

doi:10.1016/j.ijantimicag.2016.06.014

Cited by 135 publications

(103 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As resistant organisms exist in humans, animals, food, and the environment-and the main driver of this resistance is antimicrobial use-a One Health conceptual framework for surveillance and control can be promoted. 18 Moreover, in a region such as SEAR consisting of many and varied socioeconomic environments, policies should be context dependent and based on economic data, to avoid a negative effect on vulnerable populations and social inequity. Within the region, a One Health approach has been used for some policy decisions (table 4, table 5).…”

Section: Key Messagesmentioning

confidence: 99%

Antimicrobial policy interventions in food animal production in South East Asia

Goutard

Bordier

Calba

et al. 2017

BMJ

View full text Add to dashboard Cite

show abstract

Section: Key Messagesmentioning

confidence: 99%

Antimicrobial policy interventions in food animal production in South East Asia

Goutard

Bordier

Calba

et al. 2017

BMJ

View full text Add to dashboard Cite

show abstract

“…In particular, the economic dimensions require a wide assessment beyond the obvious cost benefit analysis to include the less tangible benefits to human and animal health and welfare [148,150,151].…”

Section: But Is There Proof Of Concept For An Oh Approach and Its Addmentioning

confidence: 99%

Roadmap to a One Health agenda 2030.

Queenan

Garnier²,

Nielsen³

et al. 2017

CABI Reviews

View full text Add to dashboard Cite

The current fragmented framework of health governance for humans, animals and environment, together with the conventional linear approach to solving current health problems, is failing to meet today's health challenges and is proving unsustainable. Advances in healthcare depend increasingly on intensive interventions, technological developments and expensive pharmaceuticals. The disconnect grows between human health, animal health and environmental and ecosystems health. Human development gains have come with often unrecognized negative externalities affecting ecosystems. Deterioration in biodiversity and ecosystem services threatens to reverse the health gains of the last century. A paradigm shift is urgently required to de-sectoralize human, animal, plant and ecosystem health and to take a more integrated approach to health, One Health (OH). The Sustainable Development Goals (SDGs) offer a framework and unique opportunity for this. Through analysing individual SDGs, we argue the feasibility of an OH approach towards achieving them. Feasibility assessments and outcome evaluations are often constrained by sectoral politics within a national framework, historic possession of expertise, as well as tried and tested metrics. OH calls for a better understanding, acceptance and use of a broader and transdisciplinary set of assessment metrics. Key objectives of OH are presented: that humans reconnect with our natural past and accept our place in, and dependence on our planet's ecosystems; and that we recognize our dependence on ecosystem services, the impact of our development thereon and accept our responsibility towards future generations to address this. Several action points are proposed to meet these objectives.Keywords: One Health, Health governance, Health policy, Sustainable development goals, Ecosystems health, Global health, Planetary Health Review Methodology: We reviewed academic papers and on line resources for definitions of health for each sector (human, animal, wildlife, plant and ecosystem health). The 17 Sustainable Development Goals (SDGs) and the official lists of diseases published by WHO and the OIE were collated and analysed for their suitability for an integrated approach to management. Selected SDGs were chosen as examples to demonstrate the feasibility of an integrated or one Health approach, which was supported by reviewing the relevant literature for each.

show abstract

“…A ntimicrobial resistance (AMR) is a global problem that requires a coordinated response to prevent further erosion of the ability to address established and emerging threats to human health (1). In the United States, AMR infections cost an estimated additional $20 billion annually and associated production losses of $35 billion per year (2).…”

mentioning

confidence: 99%

“…In the United States, AMR infections cost an estimated additional $20 billion annually and associated production losses of $35 billion per year (2). In the United Kingdom, it is estimated that drug-resistant infections might account for 10 million deaths per year by 2050, with total costs of $100 trillion in lost output (1). Collection of AMR surveillance and antibiotic consumption data is an essential approach to both defining the scope of the resistance problem and developing interventions that improve appropriate use of antibiotics and decrease resistance selection pressure (1,3).…”

mentioning

confidence: 99%

“…In the United Kingdom, it is estimated that drug-resistant infections might account for 10 million deaths per year by 2050, with total costs of $100 trillion in lost output (1). Collection of AMR surveillance and antibiotic consumption data is an essential approach to both defining the scope of the resistance problem and developing interventions that improve appropriate use of antibiotics and decrease resistance selection pressure (1,3). Another important effort is to understand the mechanisms of resistance whereby bacteria avoid the effects of antibiotics and to use this information to develop new agents, or modify older agents, such that potent activity is retained against the key target pathogens (4-6).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011

Pfaller

Huband

Rhomberg

et al. 2017

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Omadacycline is a broad-spectrum aminomethylcycline in late-stage clinical development for the treatment of acute bacterial skin and skin structure infections and community-acquired pneumonia as an oral and an intravenous oncedaily formulation. In this study, omadacycline and comparators were tested against 69,246 nonduplicate bacterial isolates collected prospectively during 2010 and 2011 from medical centers in Asia-Pacific (11,397 isolates), Europe (23,490 isolates), Latin America (8,038 isolates), and North America (26,321 isolates). Omadacycline was tested by broth microdilution following Clinical and Laboratory Standards Institute M07-A10 (2015) methods. A total of 99.9% of Staphylococcus aureus isolates were inhibited by Յ2 g/ml of omadacycline (MIC 50/90 , 0.12/0.25 g/ml), including 100.0% of methicillin-susceptible S. aureus isolates and 99.8% of methicillin-resistant S. aureus isolates. Omadacycline potencies were comparable for Streptococcus pneumoniae (MIC 50/90 , 0.06/0.06 g/ml), viridans group streptococci (MIC 50/90 , 0.06/0.12 g/ml), and beta-hemolytic streptococci (MIC 50/90 , 0.06/0.12 g/ml) regardless of species and susceptibility to penicillin. Omadacycline was active against Enterobacteriaceae and was most active against Escherichia coli (MIC 50/90 , 0.5/2 g/ml), Enterobacter aerogenes (MIC 50/90 , 2/4 g/ml), Klebsiella oxytoca (MIC 50/90 , 1/4 g/ml), and Citrobacter spp. (MIC 50/90 , 1/4 g/ml). Omadacycline was active against Haemophilus influenzae (MIC 50/90 , 1/1 g/ml) regardless of ␤-lactamase status and against Moraxella catarrhalis (MIC 50/90 , 0.12/0.25 g/ml). The potent activity of omadacycline against Gram-positive and Gramnegative bacteria indicates that omadacycline merits further study in serious infections in which multidrug resistance and mixed Gram-positive and Gram-negative infections may be a concern.KEYWORDS aminomethylcycline, omadacycline, resistance, surveillance A ntimicrobial resistance (AMR) is a global problem that requires a coordinated response to prevent further erosion of the ability to address established and emerging threats to human health (1). In the United States, AMR infections cost an estimated additional $20 billion annually and associated production losses of $35 billion per year (2). In the United Kingdom, it is estimated that drug-resistant infections might account for 10 million deaths per year by 2050, with total costs of $100 trillion in lost output (1). Collection of AMR surveillance and antibiotic consumption data is an essential approach to both defining the scope of the resistance problem and developing interventions that improve appropriate use of antibiotics and decrease resistance selection pressure (1, 3). Another important effort is to understand the mechanisms of resistance whereby bacteria avoid the effects of antibiotics and to use this information to develop new agents, or modify older agents, such that potent activity is retained against the key target pathogens (4-6). Downloaded fromTetracyclines are broad-spectrum age...

show abstract

A One Health approach to antimicrobial resistance surveillance: is there a business case for it?

Cited by 135 publications

References 24 publications

Antimicrobial policy interventions in food animal production in South East Asia

Antimicrobial policy interventions in food animal production in South East Asia

Roadmap to a One Health agenda 2030.

Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011

Contact Info

Product

Resources

About